Pharma Deals Review, Vol 2005, No 59 (2005)

Font Size:  Small  Medium  Large

Competition Forces Organon and J&J to Terminate Co-Promotion of Risperdal®

Business Review Editor

Abstract


Organon terminated the co-promotion agreement with Janssen-Cilag for the antipsychotic drug, Risperdal® (risperidone) owing to the existence of Organon’s potential competiting product Asenapine. The deal could be worth up to €150 M (US$194 M) to Organon.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.